Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
LEXINGTON, Mass., April 28, 2017 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EDT. The conference ID number is 11306169. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
